Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a new update report published by VASRO GmbH ("VASRO") reviewing Ainos' planned expansion of its AI Nose platform into patient-level breath intelligence.

The VASRO update reviews Ainos' recently announced one-year research program with National Taiwan University, scheduled to begin on July 1, 2026, to evaluate whether AI-analyzed breath patterns may help distinguish acute exacerbations of chronic obstructive pulmonary disease ("COPD") from acute decompensated heart failure among patients presenting with shortness of breath. While these conditions can appear similar on arrival, they may require different clinical responses.

VASRO characterized the program as an expansion of Ainos' AI Nose platform from environmental sensing into patient-level breath analysis, extending Smell ID into a new source of real-world scent data. By digitizing breath-related scent patterns into data, the program may further broaden the datasets supporting the Company's Smell Language Model ("SLM") across diverse use-cases.

"This research program applies our AI Nose platform to a high-value emergency-care challenge where time and diagnostic clarity matter," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "It also reflects the continued expansion of Smell AI from sensing environments toward capturing and interpreting patient-level breath data."

The full VASRO report is available here:

https://vasro.de/wp-content/uploads/2026/06/VASRO-GmbH_Update_Report_Ainos_Inc_06222026_EN.pdf